Sugi Predict

Sugi Predict / Targets / ACACB

ACACB

Acetyl-CoA carboxylase 2 · O00763 · ACACB on Sugi Atlas →

164,443 patent compounds predicted against ACACB, 55,019 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL163053 SCHEMBL163053 1.00 20/20
SCHEMBL163363 SCHEMBL163363 1.00 20/20
SCHEMBL164011 SCHEMBL164011 1.00 20/20
SCHEMBL164279 SCHEMBL164279 1.00 20/20
SCHEMBL164517 SCHEMBL164517 1.00 20/20
SCHEMBL164953 SCHEMBL164953 1.00 20/20
SCHEMBL165567 SCHEMBL165567 1.00 20/20
SCHEMBL165737 SCHEMBL165737 1.00 20/20
SCHEMBL165796 SCHEMBL165796 1.00 20/20
SCHEMBL165904 SCHEMBL165904 1.00 20/20
SCHEMBL165922 SCHEMBL165922 1.00 20/20
SCHEMBL166084 SCHEMBL166084 1.00 20/20
SCHEMBL166118 SCHEMBL166118 1.00 20/20
SCHEMBL166249 SCHEMBL166249 1.00 20/20
SCHEMBL166470 SCHEMBL166470 1.00 20/20
SCHEMBL168058 SCHEMBL168058 1.00 20/20
SCHEMBL168605 SCHEMBL168605 1.00 20/20
SCHEMBL173446 SCHEMBL173446 1.00 20/20
SCHEMBL173447 SCHEMBL173447 1.00 20/20
SCHEMBL173489 SCHEMBL173489 1.00 20/20

Clinical trials — most relevant to ACACB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis PHASE4RECRUITING
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia PHASE3COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis PHASE2ACTIVE_NOT_RECRUITING
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects PHASE2COMPLETED
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Effects of Experimental Hyperketonemia on Myocardial Metabolism EARLY_PHASE1COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
Hepatic Energy Fluxes in NASH and NAS Patients nanACTIVE_NOT_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Diet Induced Ketosis for Brain Injury - A Feasibility Study nanCOMPLETED
Intestinal Ketone Bodies Interfere With the Glycemic Control nanCOMPLETED
Effects of Ketones on Muscle Wasting During Caloric Restriction in Lean Females nanCOMPLETED
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease nanENROLLING_BY_INVITATION
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock nanCOMPLETED
Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate nanCOMPLETED
Effect of Cocoa Polyphenols Supplementation on Cardiovascular Risk of Postmenopausal Women nanUNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
McArdle Disease Treatment by Ketogenic Diet nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
NASH AMPK Exercise Dosing (AMPED) Trial nanRECRUITING
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ACACB binder may also engage these)

ProteinNameSimilarity
E9Q4Z2 — 1.000 E9Q4Z2 →
Q8BPM2 — 0.981 Q8BPM2 →
Q8IYB8 — 0.981 Q8IYB8 →
Q60HG1 — 0.980 Q60HG1 →
Q5ZKK7 — 0.979 Q5ZKK7 →
Q1RMT1 — 0.979 Q1RMT1 →
P49135 — 0.979 P49135 →
O35099 — 0.978 O35099 →
A4IID4 — 0.978 A4IID4 →
Q7ZVV1 — 0.978 Q7ZVV1 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.978 landscape →
Q4G005 — 0.978 Q4G005 →
PI4KB Phosphatidylinositol 4-kinase beta 0.978 landscape →
Q7ZY60 — 0.977 Q7ZY60 →
Q5RA62 — 0.977 Q5RA62 →
Q80YD1 — 0.977 Q80YD1 →
P19447 — 0.977 P19447 →
B1MTG7 — 0.976 B1MTG7 →
B4UT09 — 0.976 B4UT09 →
Q642Q1 — 0.976 Q642Q1 →
Q8CI95 — 0.976 Q8CI95 →
B0KWC1 — 0.976 B0KWC1 →
B2KI64 — 0.976 B2KI64 →
Q5ZJT0 — 0.975 Q5ZJT0 →
Q9H8M5 — 0.975 Q9H8M5 →
P00367 — 0.975 P00367 →
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 0.975 landscape →
Q9BXW6 — 0.975 Q9BXW6 →
Q8BML1 — 0.975 Q8BML1 →
Q9BXB4 — 0.975 Q9BXB4 →